We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+4.78%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$599M
AUM Growth
+$24.9M
Cap. Flow
+$44M
Cap. Flow %
7.35%
Top 10 Hldgs %
69.44%
Holding
34
New
7
Increased
17
Reduced
7
Closed
2

Top Buys

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$21.8M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$21.5M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$20.7M
4
EW icon
Edwards Lifesciences
EW
+$13.5M
5
PTCT icon
PTC Therapeutics
PTCT
+$10.7M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$33.2M
2
AVXS
AveXis, Inc. Common Stock
AVXS
+$18.7M
3
BLUE
bluebird bio
BLUE
+$14.3M
4
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$9.62M
5
FSTX
F-star Therapeutics, Inc. Common Stock
FSTX
+$4.2M

Sector Composition

Rank Sector Weight
1 Healthcare 90.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OXFD
26
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$5.25M 0.88%
375,792
-656,578
-64% -$9.62M
APYX icon
27
Apyx Medical
APYX
$173M
$4.56M 0.76%
1,752,611
+613,011
+54% +$1.91M
ZYNE
28
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$2.54M 0.42%
202,859
+2,859
+1% +$32.8K
FPRX
29
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$2.2M 0.37%
+100,377
New +$3.23M
ARGX icon
30
argenx
ARGX
$54.6B
$1.59M 0.27%
25,260
+354
+1% +$11.6K
RVNC
31
DELISTED
Revance Therapeutics, Inc.
RVNC
$824K 0.14%
+23,038
New +$662K
SRTSW
32
DELISTED
Sensus Healthcare, Inc. Warrant expiring on 06/08/2020
SRTSW
$98K 0.02%
151,400
-3,600
-2% -$4.13K
BLUE
33
DELISTED
bluebird bio
BLUE
– –
-8,035
Closed -$14.3M
FSTX
34
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
– –
-62,274
Closed -$4.2M
1
2

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FPAS
Focus Partners Advisor Solutions Saint Louis, Missouri $9.92B AUM 21.52% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return

RTW Investments's Q4 2017 Portfolio in Review

As of Q4 2017, RTW Investments held 34 positions worth $599M, up 4.3% from $574M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

RTW Investments deployed $44M of net new capital in Q4 2017, opening 7 new positions and adding to 17 existing holdings. Its largest new stake was Edwards Lifesciences: 369,000 shares worth $13.9M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $33.2M trimmed.

  • RTW Investments's largest Q4 2017 buy was Edwards Lifesciences: 369,000 shares worth $13.9M.
  • RTW Investments added most to Dicerna Pharmaceuticals, Inc. in Q4 2017, an estimated $21.8M increase.
  • RTW Investments's biggest Q4 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $33.2M.
  • RTW Investments fully exited bluebird bio in Q4 2017, selling an estimated $14.3M.
  • RTW Investments's ten largest holdings make up 69% of its $599M portfolio in Q4 2017.
  • RTW Investments opened 7 new positions and closed 2 in Q4 2017.
  • RTW Investments's portfolio value rose 4.3% quarter-over-quarter to $599M.

Based on RTW Investments's 13F filing for Q4 2017, filed 14 Feb 2018.